Morningstar maintains fair value price for Australia's ALS on demand for mineral testing

** Morningstar maintains its fair value estimate on Australia's ALS Limited ALQ.AX at A$16.70 per share

** Investment research firm says recent data supports near-term demand for mineral testing services in Australia; forecasts 15% commodities EBITDA growth in FY27

** Remains cautious on the long-term outlook for co; anticipates rising commodities EBITDA till 2030, after which normalized commodity prices will leave EBITDA flat

** Expects life sciences segment to drive long-term growth on rising demand for environmental, food, and pharmaceutical testing and tighter regulations; forecasts life sciences to contribute 63% of earnings by FY2031

** 11 of 13 analysts rate the stock "buy" or higher, 1 "hold" and 1 "sell" or lower; their median PT is A$26.00 — LSEG data

** Stock down 6.4% for the year